LB-100 is primarily investigated for its potential in cancer therapy. It functions as a protein phosphatase 2A (PP2A) inhibitor, which plays a role in regulating cell growth and apoptosis. By inhibiting PP2A, LB-100 can enhance the effectiveness of other cancer treatments, such as chemotherapy and radiation, by making cancer cells more susceptible to these therapies. Research has shown promising results in preclinical studies, particularly in reducing tumor growth and improving survival rates in various cancer models. Additionally, LB-100 is being explored for its potential to overcome drug resistance in certain cancers, offering a new avenue for treatment where traditional methods have failed. Clinical trials are ongoing to further evaluate its safety and efficacy in human patients.